• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Abcam plc

    12/15/23 4:21:28 PM ET
    $ABCM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABCM alert in real time by email
    S-8 POS 1 d562441ds8pos.htm S-8 POS S-8 POS

    As filed with the United States Securities and Exchange Commission on December 15, 2023

    Registration No. 333-252514

    Registration No. 333-257893

    Registration No. 333-263946

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    Post-Effective Amendment No. 1 (333-252514)

    Post-Effective Amendment No. 1 (333-257893)

    Post-Effective Amendment No. 1 (333-263946)

    to

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Abcam Limited

    (Exact name of registrant as specified in its charter)

     

     

     

    United Kingdom   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    Discovery Drive

    Cambridge Biomedical Campus

    Cambridge, CB2 0AX

    United Kingdom

      Not Applicable
    (Address of Principal Executive Offices)   (Zip Code)

    ABCAM PLC LONG-TERM INCENTIVE PLAN

    ABSHARE

    THE ABCAM PLC ANNUAL BONUS PLAN

    ABCAM 2005 SHARE OPTION SCHEME

    THE ABCAM 2015 SHARE OPTION PLAN

    ABCAM PLC PROFITABLE GROWTH INCENTIVE PLAN

    ABCAM PLC GROWTH PLAN

    (Full title of the plan)

    Abcam Inc.

    152 Grove Street

    Suite 1100

    Waltham, Massachusetts

    02453

    (Name and address of agent for service)

    (888) 772-2226

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Lorenzo Corte, Esq.

    Skadden, Arps, Slate, Meagher & Flom (UK) LLP

    22 Bishopsgate

    London EC2M 4BQ

    United Kingdom

    +44 20 7519 7000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated Filer   ☒    Accelerated Filer   ☐
    Non-Accelerated Filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the following Registration Statements on Form S-8 (the “Registration Statements”) of Abcam Limited, a private limited company under the laws of England and Wales (“Abcam”):

     

      •  

    Registration Statement on Form S-8, File No. 333-252514, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 28, 2021, pertaining to 4,607,314 ordinary shares, nominal value £0.002 per share, of Abcam (“Ordinary Shares”), issuable under (i) the Abcam plc Long-Term Incentive Plan, (ii) Abshare, (iii) the Abcam plc Annual Bonus Plan, (iv) the Abcam 2005 Share Option Scheme and (v) the Abcam 2015 Share Option Plan;

     

      •  

    Registration Statement on Form S-8, File No. 333-257893, filed with the SEC on July 14, 2021, pertaining to 7,936,170 Ordinary Shares issuable under the Abcam plc Profitable Growth Incentive Plan; and

     

      •  

    Registration Statement on Form S-8, File No. 333-263946, filed with the SEC on March 29, 2022, pertaining to 3,500,000 Ordinary Shares issuable under the Abcam plc Growth Plan.

    On December 6, 2023, Diadem Holdco Limited (“Purchaser”), an indirect wholly owned subsidiary of Danaher Corporation (“Danaher”), acquired all of the issued and outstanding Ordinary Shares and American depositary shares of the Company (other than certain ordinary shares held by Danaher) pursuant to an agreement dated August 26, 2023, by and among the Company, Danaher and Purchaser, in accordance with a scheme of arrangement (the “Scheme”) under Part 26 of the U.K. Companies Act 2006.

    As a result of the Scheme, the Company has terminated any and all offerings of the Ordinary Shares pursuant to the Registration Statements. In accordance with an undertaking contained in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the Ordinary Shares registered under the Registration Statements that remain unsold at the termination of the offering, the Company hereby removes from registration all of the Ordinary Shares registered but unsold under the Registration Statements as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, United Kingdom, on December 15, 2023.

     

    ABCAM LIMITED

    By:

     

    /s/ Alan Hirzel

    Name:

     

    Alan Hirzel

    Title:

     

    Chief Executive Officer

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.


    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Abcam Limited has signed this registration statement on December 15, 2023.

     

    ABCAM INC.

    By:

     

    /s/ Theresa Boni

    Name:

     

    Theresa Boni

    Title:

     

    Assistant Secretary

    Get the next $ABCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCM

    DatePrice TargetRatingAnalyst
    6/20/2023$23.00 → $22.00Outperform → Sector Perform
    RBC Capital Mkts
    6/16/2023$25.00Neutral → Buy
    BofA Securities
    12/14/2022$15.00Hold
    Deutsche Bank
    More analyst ratings

    $ABCM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Abcam plc

      15-12G - Abcam plc (0001492074) (Filer)

      12/18/23 4:17:02 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:24:56 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Abcam plc

      S-8 POS - Abcam plc (0001492074) (Filer)

      12/15/23 4:21:28 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ABCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Completes Acquisition of Abcam

      WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023. As a result, Abcam has become an indirect wholly owned subsidiary of Danaher. Trading of Abcam ADSs on Nasdaq has been suspended. The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS

      12/6/23 7:30:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme‘). The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘). Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme. Closing of the T

      12/4/23 4:01:00 PM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials
    • Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

      Abcam plc (NASDAQ:ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE:DHR) (‘Danaher') for $24.00 per share in cash (the ‘Transaction'), today announced that all Identified Clearances required in connection with the Transaction have been obtained from the relevant Governmental Authorities. The Transaction remains subject to the sanction of the Scheme by the High Court of Justice of England and Wales and the satisfaction or waiver (if applicable) of certain other customary closing conditions as set out in Par

      11/17/23 7:00:00 AM ET
      $ABCM
      $DHR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Machinery/Components
      Industrials

    $ABCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Abcam downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Abcam from Outperform to Sector Perform and set a new price target of $22.00 from $23.00 previously

      6/20/23 7:17:42 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Abcam upgraded by BofA Securities with a new price target

      BofA Securities upgraded Abcam from Neutral to Buy and set a new price target of $25.00

      6/16/23 7:25:35 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Abcam with a new price target

      Deutsche Bank initiated coverage of Abcam with a rating of Hold and set a new price target of $15.00

      12/14/22 7:33:18 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care